These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33259959)

  • 21. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma.
    Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L
    Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
    Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
    Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib.
    Lou E; Schomaker M; Wilson JD; Ahrens M; Dolan M; Nelson AC
    Cancer Biol Ther; 2016 Oct; 17(10):1010-1016. PubMed ID: 27682250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
    Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
    Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
    Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
    Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vismodegib and Physeal Closure in a Pediatric Patient.
    Lucas JT; Wright KD
    Pediatr Blood Cancer; 2016 Nov; 63(11):2058. PubMed ID: 26864592
    [No Abstract]   [Full Text] [Related]  

  • 28. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
    Abidi A
    Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
    Frampton JE; Basset-Séguin N
    Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
    Juhasz ML; Marmur ES
    J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
    LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
    Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib.
    Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P
    Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.
    Mpekris F; Papageorgis P; Polydorou C; Voutouri C; Kalli M; Pirentis AP; Stylianopoulos T
    J Control Release; 2017 Sep; 261():105-112. PubMed ID: 28662901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
    Dirix L; Rutten A
    Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.
    Kumar V; Mundra V; Peng Y; Wang Y; Tan C; Mahato RI
    Theranostics; 2018; 8(15):4033-4049. PubMed ID: 30128034
    [No Abstract]   [Full Text] [Related]  

  • 39. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hedgehog pathway inhibition and the race against tumor evolution.
    Atwood SX; Chang AL; Oro AE
    J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.